Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a glo | Embecta ...
Embecta hits multi-year lows on GLP-1 fears, but offers 6%+ yield and deep value. Read the latest analysis on the stock and ...
Your Ozempic is set to get cheaper. But with over 50 brands of the same molecule hitting the market this year, which one will ...
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...
Novo Nordisk A/S won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to that of rival Eli Lilly & Co.’s competing shot ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...
Health on MSN
Do peptide injections really work—and are they safe?
Fact checked by Nick Blackmer Peptides have become a buzzy wellness trend, promoted for longevity and a range of health ...
For people with sensitivity, encountering an allergen can within seconds turn into a respiratory emergency. This is what you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results